These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 20857319

  • 1. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF, Schubert AD, Vassella E, Mariani L.
    J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
    Fiano V, Trevisan M, Trevisan E, Senetta R, Castiglione A, Sacerdote C, Gillio-Tos A, De Marco L, Grasso C, Magistrello M, Tondat F, Rudà R, Cassoni P, Soffietti R, Merletti F.
    J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
    [Abstract] [Full Text] [Related]

  • 5. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
    Sardi I, Cetica V, Massimino M, Buccoliero AM, Giunti L, Genitori L, Aricò M.
    Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
    [Abstract] [Full Text] [Related]

  • 6. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.
    Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.
    World J Surg Oncol; 2013 Oct 25; 11():284. PubMed ID: 24160898
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.
    J Neurooncol; 2009 Mar 25; 92(1):23-31. PubMed ID: 19011762
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.
    Neurology; 2010 Oct 26; 75(17):1560-6. PubMed ID: 20975057
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A, Chautard E, Vaurs-Barrière C, Pereira B, Müller-Barthélémy M, Court F, Biau J, Pinto AA, Kémény JL, Khalil T, Karayan-Tapon L, Verrelle P, Costa BM, Arnaud P.
    Carcinogenesis; 2016 Feb 26; 37(2):169-176. PubMed ID: 26717998
    [Abstract] [Full Text] [Related]

  • 14. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W, DIRECTOR Study Group.
    Clin Cancer Res; 2015 May 01; 21(9):2057-64. PubMed ID: 25655102
    [Abstract] [Full Text] [Related]

  • 15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
    Pediatr Blood Cancer; 2007 Apr 01; 48(4):403-7. PubMed ID: 16609952
    [Abstract] [Full Text] [Related]

  • 16. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.
    Neuro Oncol; 2012 Jan 01; 14(1):109-16. PubMed ID: 22039037
    [Abstract] [Full Text] [Related]

  • 17. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
    Buttarelli FR, Massimino M, Antonelli M, Lauriola L, Nozza P, Donofrio V, Arcella A, Oliva MA, Di Rocco C, Giangaspero F.
    Childs Nerv Syst; 2010 Aug 01; 26(8):1051-6. PubMed ID: 20552207
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
    Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, Benson A, Woods AM, Cher L.
    Neuro Oncol; 2010 May 01; 12(5):500-7. PubMed ID: 20406900
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MGMT promoter methylation in pediatric high-grade gliomas.
    Fassan M, Tassone E, Onisto M, Perilongo G, D'Avella D, Gardiman MP.
    Childs Nerv Syst; 2011 Jan 01; 27(1):7-8. PubMed ID: 21052697
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.